Findings of Misconduct in Science, 16366-16367 [07-1616]
Download as PDF
16366
Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Notices
Trans No.
Acquiring
Acquired
Entities
20070928 .........................
Aktiegolaget Volvo .............................
Ingersoll-Rand Company Limited ......
20070932 .........................
Beacon Roofing Supply, Inc ..............
20070940 .........................
OCM Principal Opportunities Fund
IV, lL.P.
OCM Opportunities Fund VII, L.P .....
Ambassadors international, Inc .........
AP Berry Holdings, LLC ....................
Vestar Capital Partners V, L.P ..........
Graham Partners II, L.P ....................
Apollo Investment Fund VI, L.P ........
Apollo Investment Fund V, L.P .........
Iconix Brand Group, Inc ....................
John D. Baker II ................................
Monomoy Capital Partners, L.P ........
North Coast Commercial Roofing
Systems, Inc.
EXCO Resources, Inc .......................
Blaw-Knox Construction Equipment
Corporation.
North Coast Commercial Roofing
Systems, Inc.
EXCO Resources, Inc.
20070944
20070949
20070950
20070951
20070952
20070953
20070954
20070968
20070970
20070971
.........................
.........................
.........................
.........................
.........................
.........................
.........................
.........................
.........................
.........................
20070974
20070975
20070977
20070982
20070984
.........................
.........................
.........................
.........................
.........................
20070986 .........................
20070991 .........................
20070995 .........................
Zurich Financial Services ..................
IDB Holding Corporation Ltd .............
LPL Investment Holdings, Inc ...........
Spire Capital Partners II, L.P ............
Marathon Special Opportunity Master
Fund, Ltd.
CRFRC–D Holdings, Inc ...................
Ares Corporate Opportunities Fund,
L.P.
JLL Partners Fund, V, L.P ................
For Further Information Contact:
Sandra M. Peay, Contact Representative
or Renee Hallman, Contact
Representative. Federal Trade
Commission, Premerger Notification
Office, Bureau of Competition, Room H–
303, Washington, DC 20580, (202) 326–
3100.
By Direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 07–1646 Filed 4–3–07; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the National Coordinator for
Health Information Technology;
American Health Information
Community Population Health and
Clinical Care Connections Workgroup
Meeting
jlentini on PROD1PC65 with NOTICES
Meeting cancellation.
17:57 Apr 03, 2007
Jkt 211001
DEG Acquisitions, LLC ......................
EXCO Resources, Inc .......................
DEG Acquisitions, LLC.
EXCO Resources, Inc.
Patheon Inc .......................................
Patheon Inc.
April 20, 2007,
from 10 a.m., to 3:30 p.m. Eastern
Daylight Time.
ADDRESSES: Hubert H. Humphrey
Building (200 Independence Avenue,
SW., Washington, DC 20201), Room
505A. Please bring photo ID for entry to
a Federal building).
FOR FURTHER INFORMATION CONTACT:
https://www.hhs.gov/healthit/ahic/
population/.
CANCELED DATE/TIME:
BILLING CODE 4150–24–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Misconduct in Science
SUMMARY: This notice announces the
cancellation of the 15th meeting of the
American Health Information
Community Population Health and
Clinical Care Connections Workgroup
[formerly Biosurvellance Workgroup] in
accordance with the Federal Advisory
Committee Act (Pub. L. 92–463, 5
U.S.C., App.)
VerDate Aug<31>2005
Bristol West Holdings, Inc .................
Susan W. Shoval ...............................
Pacific Mutual Holding Company ......
Professional Bull Riders, Inc .............
SPX Corporation ...............................
EXCO Resources, Inc.
Windstar Sail Cruises Limited.
Berry Plastics Group, Inc.
Huish Detergents, Inc.
Berry Plastics Group, Inc.
Berry Plastics Group, Inc.
Berry Plastics Group, Inc.
ROCAWEAR LICENSING, LLC.
Holdco.
Anchor Hocking CG Operating Company, LLC; Anchor Hocking Operating Company, LLC, Anchor
Hocking Operating Company LLC.
Bristol West Holdings, Inc.
Guard Financial Group, Inc.
Pacific Select Group LLC.
Professional Bull Riders, Inc.
General Signal UK Ltd.
Dated: March 27, 2007.
Judith Sparrow,
Director, American Health Information
Community, Office of Programs and
Coordination, Office of the National
Coordinator for Health Information
Technology.
[FR Doc. 07–1645 Filed 4–3–07; 8:45 am]
BILLING CODE 6750–01–M
ACTION:
EXCO Resources, Inc .......................
Carnival Corporation .........................
Berry Plastics Group, Inc ..................
Paul Danton (Dan) Huish ..................
Berry Plastics Group, Inc ..................
Berry Plastics Group, Inc ..................
Apollo Investment Fund VI, L.P ........
ROCSAN Holdings, LLC ...................
Holdco ...............................................
Global Home Products LLP, Chapter
11 debtor in possession.
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
SUMMARY: Notice is hereby given that on
March 12, 2007 the Department of
Health and Human Services (HHS)
Debarring Official, on behalf of the
Secretary of HHS, issued a final notice
of debarment based on the misconduct
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
in science findings of the U.S. Public
Health Service (PHS) in the following
case:
Rebecca Uzelmeier (formerly known
as Rebecca Marcus), Michigan State
University: Based on the report of an
investigation by Michigan State
University (MSU) and additional
information obtained by the Office of
Research Integrity (ORI) during its
oversight review, ORI found that
Rebecca Uzelmeier, former doctoral
student, Department of Pharmacology
and Toxicology, MSU, committed
misconduct in science by intentionally
and knowingly fabricating and falsifying
data in research supported by National
Institute of Environmental Health
Sciences (NIEHS), National Institutes of
Health (NIH), granted R01 ES02520.
ORI issued a charge letter
enumerating the above findings of
misconduct in science. However, on
October 12, 2006, Ms. Uzelmeier filed a
request for a hearing under 42 CFR part
93 to dispute these findings before the
U.S. Department of Health and Human
Services (HHS) Departmental Appeals
Board (DAB). On October 19, 2006, ORI
moved to dismiss Ms. Uzelmeier’s
hearing request because it failed to
create a genuine dispute of either
material fact or law, as required under
42 CFR 93.504. On March 5, 2007, the
Administrative Law Judge (ALJ) with
the DAB ruled in ORI’s favor and
dismissed Ms. Uzelmeier’s hearing
request pursuant to 42 CFR 93.504(a)(2).
E:\FR\FM\04APN1.SGM
04APN1
jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Notices
The ALJ found that Ms. Uzelmeier’s
hearing request raised defenses that
either were immaterial to the charges of
misconduct in science or that the ALJ
had no authority to grant Ms.
Uzelmeier’s request for relief under Part
93.
Specifically, Ms. Uzelmeier
knowingly and intentionally;
• Fabricated and falsified data in her
research notebook primarily by multiple
instances of using data/results generated
from one experiment to represent data/
results purportedly obtained from one
or more entirely different experiments;
and
• Fabricated and falsified data in her
thesis entitled ‘‘Characterization of the
Molecular Mechanism(s) Underlying the
Interaction(s) between 2,3,7,8tetrachlorodibenzo-p-Dioxin Mediated
and Interferon Gamma Mediated Signal
Transduction,’’ including falsifying and
fabricating autoradiographic films,
computer image files scanned from
those films, numerical data reduced
from those computer files,
documentation of those results in her
black three-ring binder, and data in
associated multiple figures and
projection slides.
Ms. Uzlmeier’s research concerned
the interaction between the
environmental toxin, dioxin, and a
cytokine, interferon, on cellular
signaling in the immune system. The
approach was to exploit dioxin, or
‘‘TCDD’’ (2,3,7,8-tetrachlorodibenzo-pdioxin), as a probe that suppresses the
immune system to delineate a role for
the aryl hydrocarbon receptor protein
(AhR), which is a cytosolic receptor that
can be transported to the nucleus to also
act as a nuclear transcription factor. The
specific aim was to determine whether
the mechanism of action of a naturally
occurring regulatory factor, interferon-g
(IFN-g), to antagonize the
immunosuppressive actions of dioxin,
was through reduced AhR signaling.
Ms. Uzelmeier’s actions caused the
withdrawal of a manuscript that had
been submitted for publication, the
withdrawal of her mentor’s PHS grant
application, and her dismissal from
graduate school.
The following administrative actions
have been implemented for a period of
five (5) years, beginning on March 12,
2007:
(1) Ms. Uzelmeier has been debarred
from any contracting or subcontracting
with any agency of the United States
Government and from eligibility or
involvement in nonprocurement
programs of the United States
Government referred to as ‘‘covered
transactions’’ as defined in the
VerDate Aug<31>2005
17:57 Apr 03, 2007
Jkt 211001
debarment regulations at 2 CFR 180 and
376; and
(2) Ms. Uzelmeier is prohibited from
serving in any advisory capacity to PHS
including but not limited to service on
any PHS advisory committee, board,
and/or peer review committee, or as
consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. 07–1616 Filed 4–3–07; 8:45 am]
BILLING CODE 4160–17–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Solicitation for Nominations for
Members of the U.S. Preventive
Services Task Force
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Solicits nominations for new
members.
AGENCY:
SUMMARY: The Agency for Healthcare
Research and Quality (AHRQ) invites
nominations of individuals qualified to
serve as members of the U.S. Preventive
Services Task Force (the Task Force).
The Task Force, a standing,
independent panel of private-sector
experts in prevention and primary care,
is composed of members appointed to
serve for four-year terms with an option
for reappointment. New members are
selected each year to replace
(approximately) one fourth of the Task
Force members, i.e., those who are
completing their appointments.
Individuals nominated but not
appointed in previous years, as well as
those newly nominated, are considered
in the annual selection process.
Task Force members meet three times
a year for two days in the Washington,
DC area. Member duties include
reviewing and preparing comments (off
site) on systematic evidence reviews
prior to discussing and making
recommendations on preventive
services, drafting final recommendation
documents, and participating in
workgroups on specific topics or
methods. AHRQ particularly encourages
nominations of women, members of
minority populations, and persons with
disabilities. Interested individuals can
self nominate. Organizations and
individuals may nominate one or more
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
16367
persons qualified for membership on the
Task Force.
Qualification Requirements: The
mission of the Task Force is to produce
evidence-based recommendations on
the appropriate screening, counseling,
and provision of preventive medication
for asymptomatic patients seen in the
primary care setting. Therefore, in order
to qualify for the Task Force, an
applicant or nominee MUST
demonstrate the following:
1. Knowledge and experience in the
critical evaluation of research published
in peer reviewed literature and in the
methods of evidence review;
2. Understanding and experience in
the application of synthesized evidence
to clinical decision-making and/or
policy;
3. Expertise in disease prevention and
health promotion;
4. Ability to work collaboratively with
peers; and,
5. Clinical expertise in the primary
health care of children and/or adults,
and/or expertise in counseling and
behavioral interventions for primary
care patients. Some Task Force members
without primary health care clinical
experience may be selected based on
their expertise in methodological issues
such as medical decision making,
clinical epidemiology, behavioral
medicine, and health economics.
Strongest consideration will be given
to individuals who are recognized
nationally or intentionally for scientific
leadership within their field of
expertise. Applicants must have no
substantial conflicts of interest that
would impair the scientific integrity of
the work of the Task Force including
financial, intellectual, or other conflicts.
DATES: All nominations submitted in
writing or electronically, and received
by Thursday, May 31, 2007, will be
considered for appointment to the Task
Force.
Nominated individuals will be
selected for the Task Force on the basis
of their qualifications (in particular,
those that address the required
qualifications, outlined above) and the
current expertise needs of the Task
Force. It is anticipated that 4
individuals will be invited to serve on
the Task Force beginning in January,
2008. AHRQ will retain and consider for
future vacancies the nominations of
those not selected during this cycle.
ADDRESSES: Submit your responses
either in writing or electronically to:
Gloria Washington, ATTN: USPSTF
Nominations, Center for Primary Care,
Prevention, and Clinical Partnerships,
Agency for Healthcare Research and
Quality, 540 Gaither Road, Rockville,
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 72, Number 64 (Wednesday, April 4, 2007)]
[Notices]
[Pages 16366-16367]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-1616]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Misconduct in Science
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that on March 12, 2007 the Department
of Health and Human Services (HHS) Debarring Official, on behalf of the
Secretary of HHS, issued a final notice of debarment based on the
misconduct in science findings of the U.S. Public Health Service (PHS)
in the following case:
Rebecca Uzelmeier (formerly known as Rebecca Marcus), Michigan
State University: Based on the report of an investigation by Michigan
State University (MSU) and additional information obtained by the
Office of Research Integrity (ORI) during its oversight review, ORI
found that Rebecca Uzelmeier, former doctoral student, Department of
Pharmacology and Toxicology, MSU, committed misconduct in science by
intentionally and knowingly fabricating and falsifying data in research
supported by National Institute of Environmental Health Sciences
(NIEHS), National Institutes of Health (NIH), granted R01 ES02520.
ORI issued a charge letter enumerating the above findings of
misconduct in science. However, on October 12, 2006, Ms. Uzelmeier
filed a request for a hearing under 42 CFR part 93 to dispute these
findings before the U.S. Department of Health and Human Services (HHS)
Departmental Appeals Board (DAB). On October 19, 2006, ORI moved to
dismiss Ms. Uzelmeier's hearing request because it failed to create a
genuine dispute of either material fact or law, as required under 42
CFR 93.504. On March 5, 2007, the Administrative Law Judge (ALJ) with
the DAB ruled in ORI's favor and dismissed Ms. Uzelmeier's hearing
request pursuant to 42 CFR 93.504(a)(2).
[[Page 16367]]
The ALJ found that Ms. Uzelmeier's hearing request raised defenses that
either were immaterial to the charges of misconduct in science or that
the ALJ had no authority to grant Ms. Uzelmeier's request for relief
under Part 93.
Specifically, Ms. Uzelmeier knowingly and intentionally;
Fabricated and falsified data in her research notebook
primarily by multiple instances of using data/results generated from
one experiment to represent data/results purportedly obtained from one
or more entirely different experiments; and
Fabricated and falsified data in her thesis entitled
``Characterization of the Molecular Mechanism(s) Underlying the
Interaction(s) between 2,3,7,8-tetrachlorodibenzo-p-Dioxin Mediated and
Interferon Gamma Mediated Signal Transduction,'' including falsifying
and fabricating autoradiographic films, computer image files scanned
from those films, numerical data reduced from those computer files,
documentation of those results in her black three-ring binder, and data
in associated multiple figures and projection slides.
Ms. Uzlmeier's research concerned the interaction between the
environmental toxin, dioxin, and a cytokine, interferon, on cellular
signaling in the immune system. The approach was to exploit dioxin, or
``TCDD'' (2,3,7,8-tetrachlorodibenzo-p-dioxin), as a probe that
suppresses the immune system to delineate a role for the aryl
hydrocarbon receptor protein (AhR), which is a cytosolic receptor that
can be transported to the nucleus to also act as a nuclear
transcription factor. The specific aim was to determine whether the
mechanism of action of a naturally occurring regulatory factor,
interferon-[gamma] (IFN-[gamma]), to antagonize the immunosuppressive
actions of dioxin, was through reduced AhR signaling.
Ms. Uzelmeier's actions caused the withdrawal of a manuscript that
had been submitted for publication, the withdrawal of her mentor's PHS
grant application, and her dismissal from graduate school.
The following administrative actions have been implemented for a
period of five (5) years, beginning on March 12, 2007:
(1) Ms. Uzelmeier has been debarred from any contracting or
subcontracting with any agency of the United States Government and from
eligibility or involvement in nonprocurement programs of the United
States Government referred to as ``covered transactions'' as defined in
the debarment regulations at 2 CFR 180 and 376; and
(2) Ms. Uzelmeier is prohibited from serving in any advisory
capacity to PHS including but not limited to service on any PHS
advisory committee, board, and/or peer review committee, or as
consultant.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. 07-1616 Filed 4-3-07; 8:45 am]
BILLING CODE 4160-17-P